Covered recipient · General Payments record
LON D LYNN
Allopathic & Osteopathic Physicians Family Medicine
A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.
Saved only in this browser. No account or alerts.
General Payments · PY2022 · Entire year
$317.77
13 records · 0 disputed
“Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.”
— Centers for Medicare & Medicaid Services, Open Payments
A reported payment reflects a financial relationship a company disclosed. It does not indicate wrongdoing or a conflict of interest, and it says nothing about the quality of a provider's care.
These records are submitted to CMS and attested to by the reporting companies. CMS publishes them as reported; this site mirrors them without independent verification.
A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.
How these totals are calculated
- This total is the sum of the individual General Payments record amounts CMS published for the labeled program year(s); each record amount is used unmodified. The total itself is computed by this site. Nothing is estimated, weighted, or combined across categories.
- General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
- Methodology & Data — sourcing, labeling, and limitations.
Provider summaries generated . CMS updates this data on an annual cycle, and corrections or successful disputes made at CMS may not yet appear here. The official CMS record is authoritative for the current state. View the official CMS record ↗
By nature of payment
PY2022 · entire year · sorted by reported total
| Nature of payment | Amount | Records |
|---|---|---|
| Food and Beverage | $317.77 | 13 |
By paying entity
PY2022 · entire year · sorted by reported total
| Paying entity | Amount | Records |
|---|---|---|
| Xeris Pharmaceuticals, Inc. | $111.86 | 1 |
| Novo Nordisk Inc | $79.40 | 4 |
| Janssen Pharmaceuticals, Inc | $19.11 | 1 |
| Amneal Pharmaceuticals LLC | $16.88 | 1 |
| Amgen Inc. | $16.67 | 1 |
| Currax Pharmaceuticals LLC | $16.41 | 1 |
| Mylan Specialty L.P. | $15.59 | 1 |
| Bayer HealthCare Pharmaceuticals Inc. | $14.51 | 1 |
| Merck Sharp & Dohme LLC | $14.02 | 1 |
| SANOFI-AVENTIS U.S. LLC | $13.32 | 1 |
Page 1 of 1; records 1–13 of 13 matching records. This page contains 13 records (maximum 50), not the full filtered export. Use the CSV download for all matching records.
IndustryPayments · General Payments
LON D LYNN
NPI 1497898282 · CMS profile ID 204601
Allopathic & Osteopathic Physicians / Family Medicine
TAMPA, FL
A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.
A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.
General Payments, PY2022; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types
Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00
Page 1 of 1; records 1–13 of 13 matching records. This page contains 13 records (maximum 50), not the full filtered export.
Filtered page: https://industrypayments.org/provider/npi-1497898282?year=2022&recipient=provider#records-h
CMS source: https://openpaymentsdata.cms.gov/dataset/df01c2f8-dc1f-4e79-96cb-8208beaf143c
Cite these filtered records
The citation includes this program year, filters, data edition, and page of results.
- Plain
- LON D LYNN, NPI 1497898282, CMS profile ID 204601. General Payments, PY2022; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 1 of 1; records 1–13 of 13 matching records. This page contains 13 records (maximum 50), not the full filtered export. IndustryPayments. https://industrypayments.org/provider/npi-1497898282?year=2022&recipient=provider#records-h. Source: https://openpaymentsdata.cms.gov/dataset/df01c2f8-dc1f-4e79-96cb-8208beaf143c.
- APA 7
- IndustryPayments. (2026). LON D LYNN, NPI 1497898282, CMS profile ID 204601. General Payments, PY2022; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 1 of 1; records 1–13 of 13 matching records. This page contains 13 records (maximum 50), not the full filtered export. [Filtered data set page]. https://industrypayments.org/provider/npi-1497898282?year=2022&recipient=provider#records-h. Source: https://openpaymentsdata.cms.gov/dataset/df01c2f8-dc1f-4e79-96cb-8208beaf143c.
- Bluebook
- LON D LYNN, NPI 1497898282, CMS profile ID 204601, IndustryPayments, General Payments, PY2022; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types (Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00). Page 1 of 1; records 1–13 of 13 matching records. This page contains 13 records (maximum 50), not the full filtered export. Source: https://openpaymentsdata.cms.gov/dataset/df01c2f8-dc1f-4e79-96cb-8208beaf143c. https://industrypayments.org/provider/npi-1497898282?year=2022&recipient=provider#records-h.
Centers for Medicare & Medicaid Services, Open Payments
Citation formats are provided for reference; check the requirements of your publication.
Payment records · PY2022
Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them
General Payments · PY2022 · Physicians and non-physician practitioners · CMS publication 2026-06-30
13 matching records · $317.77 reported total · 0 disputed
Nature of payment: All payment types
Records imported here (UTC).
CSV includes CMS record IDs, source and publication dates, the data edition, and a link to these filters. Formula-like text cells are prefixed with an apostrophe for spreadsheet safety.
Showing records 1–13 of 13.
| Paying entity | Amount | Date | Nature of payment | Dispute status | Publication flags | Published | Record ID | Source |
|---|---|---|---|---|---|---|---|---|
| Xeris Pharmaceuticals, Inc. | $111.86 | 12/01/2022 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 946483565 | CMS |
| Novo Nordisk Inc | $17.26 | 07/19/2022 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 898731519 | CMS |
| Amgen Inc. | $16.67 | 03/03/2022 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 939271275 | CMS |
| Novo Nordisk Inc | $24.78 | 03/02/2022 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 898905593 | CMS |
| Mylan Specialty L.P. | $15.59 | 02/25/2022 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 963896071 | CMS |
| Amneal Pharmaceuticals LLC | $16.88 | 02/24/2022 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 956585949 | CMS |
| Novo Nordisk Inc | $17.45 | 02/23/2022 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 898855126 | CMS |
| Novo Nordisk Inc | $19.91 | 02/17/2022 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 898629311 | CMS |
| Currax Pharmaceuticals LLC | $16.41 | 02/16/2022 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 925770539 | CMS |
| Merck Sharp & Dohme LLC | $14.02 | 02/10/2022 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 944775579 | CMS |
| Janssen Pharmaceuticals, Inc | $19.11 | 02/09/2022 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 886017719 | CMS |
| Bayer HealthCare Pharmaceuticals Inc. | $14.51 | 02/02/2022 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 930058201 | CMS |
| SANOFI-AVENTIS U.S. LLC | $13.32 | 01/26/2022 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 938751865 | CMS |
By program year
All program years on this page · sorted by year
Source & provenance
- Dataset
- CMS Open Payments — General Payments
- Publisher of source data
- Centers for Medicare & Medicaid Services
- CMS publication date
- 2026-06-30
- Program years on this page
- 2019, 2020, 2021, 2022, 2023, 2024
Source files and profile matching
- Generated from
- OP_DTL_GNRL_PGYR2024_P06302026_06032026.csv
One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.
Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.
Research Payments
One row per program year and role, newest year first · amounts for the two roles are never added together
| Program year | Role | Amount | Records |
|---|---|---|---|
| PY2025 | Principal investigator | $2,774,310.43 | 131 |
| PY2024 | Recipient | $1,401.65 | 10 |
| PY2024 | Principal investigator | $1,886,016.65 | 154 |
| PY2023 | Recipient | $1,734.07 | 2 |
| PY2023 | Principal investigator | $1,613,093.87 | 174 |
| PY2022 | Recipient | $7,938.00 | 2 |
| PY2022 | Principal investigator | $1,203,947.96 | 117 |
| PY2021 | Recipient | $1,793.52 | 3 |
| PY2021 | Principal investigator | $874,519.06 | 78 |
| PY2020 | Principal investigator | $706,623.45 | 80 |
| PY2019 | Recipient | $1,208.55 | 9 |
| PY2019 | Principal investigator | $596,855.42 | 115 |
Research Payments are a separate CMS dataset, shown here separately and never added to General Payments. A research payment is often made to an institution, with this provider named as a principal investigator; each record states which role applies.
“If you are a physician who served as a principal investigator on a research study, you may see the payments associated with that research study listed under your name. This does not necessarily mean the payments are attributed to you. The dollar amount of the record corresponds to the total payment; the amounts are not attributed to each individual on the record.”
— Centers for Medicare & Medicaid Services, Open Payments Frequently Asked Questions, FAQ #12224
Research Payments records · PY2020
Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them
80 records in PY2020
| Role | Paying entity | Amount | Date | Recipient | Study | Dispute status | Published | Record ID |
|---|---|---|---|---|---|---|---|---|
| Principal investigator 1 | AstraZeneca Pharmaceuticals LP | $780.48 | 12/31/2020 | Non-covered Recipient Entity Clinical Research Of West Florida | A Randomized Double-Blind Parallel Group Multi-Center 24-Week Study Comparing the Efficacy and Safety of Three Doses of PT001 to Placebo and Open-label Spiriva Respimat in Subjects With Persistent Asthma | No dispute reported | 06/30/2026 | 736744299 |
| Principal investigator 1 | AbbVie Inc. | $1,403.55 | 12/30/2020 | Non-covered Recipient Entity CLINICAL RESEARCH OF WEST FLORIDA | M18-891 | No dispute reported | 06/30/2026 | 721202717 |
| Principal investigator 1 | Beckman Coulter, Inc. | $4,419.00 | 12/30/2020 | Non-covered Recipient Entity CLINICAL RESEARCH OF WEST FLORIDA INCORPORATED | HF Ref Interval (CHF-04-18) | No dispute reported | 06/30/2026 | 749968529 |
| Principal investigator 1 | Beckman Coulter, Inc. | $631.00 | 12/30/2020 | Non-covered Recipient Entity CLINICAL RESEARCH OF WEST FLORIDA INCORPORATED | HF Ref Interval (CHF-04-18) | No dispute reported | 06/30/2026 | 749968531 |
| Principal investigator 1 | Beckman Coulter, Inc. | $510.00 | 12/30/2020 | Non-covered Recipient Entity CLINICAL RESEARCH OF WEST FLORIDA INCORPORATED | HF Ref Interval (CHF-04-18) | No dispute reported | 06/30/2026 | 749968533 |
| Principal investigator 1 | Abbott Laboratories | $15,000.00 | 12/18/2020 | Non-covered Recipient Entity CLINICAL RESEARCH OF WEST FLORIDA INC | Abbott RealTime SARS-CoV-2 Specimen Collection Protocol | No dispute reported | 06/30/2026 | 749808011 |
| Principal investigator 1 | AbbVie Inc. | $3,386.10 | 12/03/2020 | Non-covered Recipient Entity CLINICAL RESEARCH OF WEST FLORIDA | M18-891 | No dispute reported | 06/30/2026 | 721199227 |
| Principal investigator 1 | JAZZ PHARMACEUTICALS INC. | $4,990.21 | 11/08/2020 | Non-covered Recipient Entity CLINICAL RESEARCH OF WEST FLORIDA INC | A DOUBLE-BLIND, PLACEBO-CONTROLLED, RANDOMIZED WITHDRAWAL, MULTICENTER STUDY OF THE EFFICACY AND SAFETY OF JZP-258 IN THE TREATMENT OF IDIOPATHIC HYPERSOMNIA (IH) WITH AN OPEN-LABEL SAFETY EXTENSION | No dispute reported | 06/30/2026 | 744484049 |
| Principal investigator 1 | AbbVie Inc. | $6,933.20 | 11/05/2020 | Non-covered Recipient Entity CLINICAL RESEARCH OF WEST FLORIDA | M18-891 | No dispute reported | 06/30/2026 | 721194507 |
| Principal investigator 1 | AstraZeneca UK Limited | $9,950.00 | 11/02/2020 | Non-covered Recipient Entity Clinical Research Of West Florida | A Phase 2b Multinational Randomised Double-blind Parallelgroup 24-week Placebo-controlled Study with 28-week Extension to Investigate the Use of Benralizumab in Patients with Moderate to Severe Chronic Spontaneous Urticaria | No dispute reported | 06/30/2026 | 736739431 |
| Principal investigator 1 | Novo Nordisk AS | $1,000.00 | 10/29/2020 | Non-covered Recipient Entity CLINICAL RESEARCH OF WEST FLORIDA | NN9536-4374 | No dispute reported | 06/30/2026 | 742358461 |
| Principal investigator 1 | Novo Nordisk AS | $600.00 | 10/29/2020 | Non-covered Recipient Entity CLINICAL RESEARCH OF WEST FLORIDA | NN9536-4374 | No dispute reported | 06/30/2026 | 742358463 |
| Principal investigator 1 | Novo Nordisk AS | $14,285.91 | 10/29/2020 | Non-covered Recipient Entity CLINICAL RESEARCH OF WEST FLORIDA | NN9536-4374 | No dispute reported | 06/30/2026 | 742358465 |
| Principal investigator 1 | JAZZ PHARMACEUTICALS INC. | $413.61 | 10/03/2020 | Non-covered Recipient Entity CLINICAL RESEARCH OF WEST FLORIDA INC | A DOUBLE-BLIND, PLACEBO-CONTROLLED, RANDOMIZED WITHDRAWAL, MULTICENTER STUDY OF THE EFFICACY AND SAFETY OF JZP-258 IN THE TREATMENT OF IDIOPATHIC HYPERSOMNIA (IH) WITH AN OPEN-LABEL SAFETY EXTENSION | No dispute reported | 06/30/2026 | 744483585 |
| Principal investigator 1 | JAZZ PHARMACEUTICALS INC. | $392.00 | 10/03/2020 | Non-covered Recipient Entity CLINICAL RESEARCH OF WEST FLORIDA INC | A DOUBLE-BLIND, PLACEBO-CONTROLLED, RANDOMIZED WITHDRAWAL, MULTICENTER STUDY OF THE EFFICACY AND SAFETY OF JZP-258 IN THE TREATMENT OF IDIOPATHIC HYPERSOMNIA (IH) WITH AN OPEN-LABEL SAFETY EXTENSION | No dispute reported | 06/30/2026 | 744483595 |
| Principal investigator 1 | AbbVie Inc. | $3,831.10 | 09/30/2020 | Non-covered Recipient Entity CLINICAL RESEARCH OF WEST FLORIDA | M18-891 | No dispute reported | 06/30/2026 | 721188137 |
| Principal investigator 1 | AbbVie Inc. | $3,435.45 | 09/29/2020 | Non-covered Recipient Entity CLINICAL RESEARCH OF WEST FLORIDA | M18-891 | No dispute reported | 06/30/2026 | 721187381 |
| Principal investigator 1 | AbbVie Inc. | $4,500.00 | 09/17/2020 | Non-covered Recipient Entity CLINICAL RESEARCH OF WEST FLORIDA | M16-006 | No dispute reported | 06/30/2026 | 721186245 |
| Principal investigator 1 | JAZZ PHARMACEUTICALS INC. | $244.00 | 09/15/2020 | Non-covered Recipient Entity CLINICAL RESEARCH OF WEST FLORIDA INC | A DOUBLE-BLIND, PLACEBO-CONTROLLED, RANDOMIZED WITHDRAWAL, MULTICENTER STUDY OF THE EFFICACY AND SAFETY OF JZP-258 IN THE TREATMENT OF IDIOPATHIC HYPERSOMNIA (IH) WITH AN OPEN-LABEL SAFETY EXTENSION | No dispute reported | 06/30/2026 | 744484137 |
| Principal investigator 1 | AbbVie Inc. | $5,800.00 | 09/14/2020 | Non-covered Recipient Entity CLINICAL RESEARCH OF WEST FLORIDA | M18-891 | No dispute reported | 06/30/2026 | 721185819 |
| Principal investigator 1 | JAZZ PHARMACEUTICALS INC. | $1,783.96 | 09/04/2020 | Non-covered Recipient Entity CLINICAL RESEARCH OF WEST FLORIDA INC | A DOUBLE-BLIND, PLACEBO-CONTROLLED, RANDOMIZED WITHDRAWAL, MULTICENTER STUDY OF THE EFFICACY AND SAFETY OF JZP-258 IN THE TREATMENT OF IDIOPATHIC HYPERSOMNIA (IH) WITH AN OPEN-LABEL SAFETY EXTENSION | No dispute reported | 06/30/2026 | 744483699 |
| Principal investigator 1 | Beckman Coulter, Inc. | $15,150.00 | 09/01/2020 | Non-covered Recipient Entity CLINICAL RESEARCH OF WEST FLORIDA INCORPORATED | HF Ref Interval (CHF-04-18) | No dispute reported | 06/30/2026 | 749968431 |
| Principal investigator 1 | AbbVie Inc. | $8,998.75 | 08/31/2020 | Non-covered Recipient Entity CLINICAL RESEARCH OF WEST FLORIDA | M18-891 | No dispute reported | 06/30/2026 | 721183923 |
| Principal investigator 1 | Lexicon Pharmaceuticals, Inc. | $440.00 | 08/11/2020 | Non-covered Recipient Entity CLINICAL RESEARCH OF WEST FLORIDA, INC. | EFC-14875 | No dispute reported | 06/30/2026 | 752054339 |
| Principal investigator 1 | AbbVie Inc. | $1,356.30 | 08/04/2020 | Non-covered Recipient Entity CLINICAL RESEARCH OF WEST FLORIDA | M18-891 | No dispute reported | 06/30/2026 | 721179305 |
| Principal investigator 1 | Beckman Coulter, Inc. | $3,156.00 | 08/04/2020 | Non-covered Recipient Entity CLINICAL RESEARCH OF WEST FLORIDA INCORPORATED | HF Ref Interval (CHF-04-18) | No dispute reported | 06/30/2026 | 749968405 |
| Principal investigator 1 | Novo Nordisk AS | $1,197.67 | 07/30/2020 | Non-covered Recipient Entity CLINICAL RESEARCH OF WEST FLORIDA | NN9536-4374 | No dispute reported | 06/30/2026 | 742358459 |
| Principal investigator 1 | JAZZ PHARMACEUTICALS INC. | $413.61 | 07/07/2020 | Non-covered Recipient Entity CLINICAL RESEARCH OF WEST FLORIDA INC | A DOUBLE-BLIND, PLACEBO-CONTROLLED, RANDOMIZED WITHDRAWAL, MULTICENTER STUDY OF THE EFFICACY AND SAFETY OF JZP-258 IN THE TREATMENT OF IDIOPATHIC HYPERSOMNIA (IH) WITH AN OPEN-LABEL SAFETY EXTENSION | No dispute reported | 06/30/2026 | 744483981 |
| Principal investigator 1 | JAZZ PHARMACEUTICALS INC. | $3,548.68 | 07/01/2020 | Non-covered Recipient Entity CLINICAL RESEARCH OF WEST FLORIDA INC | A DOUBLE-BLIND, PLACEBO-CONTROLLED, RANDOMIZED WITHDRAWAL, MULTICENTER STUDY OF THE EFFICACY AND SAFETY OF JZP-258 IN THE TREATMENT OF IDIOPATHIC HYPERSOMNIA (IH) WITH AN OPEN-LABEL SAFETY EXTENSION | No dispute reported | 06/30/2026 | 744483419 |
| Principal investigator 1 | AbbVie Inc. | $9,673.90 | 06/30/2020 | Non-covered Recipient Entity CLINICAL RESEARCH OF WEST FLORIDA | M18-891 | No dispute reported | 06/30/2026 | 721173015 |
| Principal investigator 1 | Janssen Research & Development, LLC | $1,500.00 | 06/29/2020 | Non-covered Recipient Entity Clnc Rsrch Of W Fl | A Study of the Efficacy and Safety of Guselkumab in Participants With Moderately to Severely Active Crohn's Disease | No dispute reported | 06/30/2026 | 719493783 |
| Principal investigator 1 | AbbVie Inc. | $1,000.00 | 06/25/2020 | Non-covered Recipient Entity CLINICAL RESEARCH OF WEST FLORIDA | M18-891 | No dispute reported | 06/30/2026 | 721172183 |
| Principal investigator 1 | Janssen Research & Development, LLC | $75.00 | 06/25/2020 | Non-covered Recipient Entity Clnc Rsrch Of W Fl | A Study of the Efficacy and Safety of Guselkumab in Participants With Moderately to Severely Active Crohn's Disease | No dispute reported | 06/30/2026 | 719493787 |
| Principal investigator 1 | Novo Nordisk AS | $9,261.00 | 06/23/2020 | Non-covered Recipient Entity CLINICAL RESEARCH OF WEST FLORIDA | NN9536-4374 | No dispute reported | 06/30/2026 | 742358453 |
| Principal investigator 1 | Novo Nordisk AS | $81.56 | 06/23/2020 | Non-covered Recipient Entity CLINICAL RESEARCH OF WEST FLORIDA | NN9536-4374 | No dispute reported | 06/30/2026 | 742358455 |
| Principal investigator 1 | Novo Nordisk AS | $1,341.57 | 06/23/2020 | Non-covered Recipient Entity CLINICAL RESEARCH OF WEST FLORIDA | NN9536-4374 | No dispute reported | 06/30/2026 | 742358457 |
| Principal investigator 1 | AbbVie Inc. | $2,712.96 | 06/18/2020 | Non-covered Recipient Entity CLINICAL RESEARCH OF WEST FLORIDA | M18-891 | No dispute reported | 06/30/2026 | 721171473 |
| Principal investigator 1 | JAZZ PHARMACEUTICALS INC. | $413.61 | 06/16/2020 | Non-covered Recipient Entity CLINICAL RESEARCH OF WEST FLORIDA INC | A DOUBLE-BLIND, PLACEBO-CONTROLLED, RANDOMIZED WITHDRAWAL, MULTICENTER STUDY OF THE EFFICACY AND SAFETY OF JZP-258 IN THE TREATMENT OF IDIOPATHIC HYPERSOMNIA (IH) WITH AN OPEN-LABEL SAFETY EXTENSION | No dispute reported | 06/30/2026 | 744483921 |
| Principal investigator 1 | Mylan Specialty L.P. | $1,000.00 | 06/09/2020 | Non-covered Recipient Entity CLINICAL RESEARCH OF WEST FLORIDA, INC. | PIFR 2 | No dispute reported | 06/30/2026 | 749850131 |
| Principal investigator 1 | AbbVie Inc. | $22,307.55 | 06/01/2020 | Non-covered Recipient Entity CLINICAL RESEARCH OF WEST FLORIDA | M18-891 | No dispute reported | 06/30/2026 | 721169291 |
| Principal investigator 1 | AbbVie Inc. | $5,454.00 | 05/28/2020 | Non-covered Recipient Entity CLINICAL RESEARCH OF WEST FLORIDA | M18-891 | No dispute reported | 06/30/2026 | 721167903 |
| Principal investigator 1 | Novo Nordisk AS | $3,179.25 | 05/26/2020 | Non-covered Recipient Entity CLINICAL RESEARCH OF WEST FLORIDA | NN9536-4374 | No dispute reported | 06/30/2026 | 742358449 |
| Principal investigator 1 | Novo Nordisk AS | $1,200.00 | 05/26/2020 | Non-covered Recipient Entity CLINICAL RESEARCH OF WEST FLORIDA | NN9536-4374 | No dispute reported | 06/30/2026 | 742358451 |
| Principal investigator 1 | JAZZ PHARMACEUTICALS INC. | $2,197.57 | 05/19/2020 | Non-covered Recipient Entity CLINICAL RESEARCH OF WEST FLORIDA INC | A DOUBLE-BLIND, PLACEBO-CONTROLLED, RANDOMIZED WITHDRAWAL, MULTICENTER STUDY OF THE EFFICACY AND SAFETY OF JZP-258 IN THE TREATMENT OF IDIOPATHIC HYPERSOMNIA (IH) WITH AN OPEN-LABEL SAFETY EXTENSION | No dispute reported | 06/30/2026 | 744483793 |
| Principal investigator 1 | Boehringer Ingelheim Pharmaceuticals, Inc. | $221.52 | 05/14/2020 | Non-covered Recipient Entity Clinical Research Of West Florida Tampa | Tio & Olo versus PBO stratified by PIFR | No dispute reported | 06/30/2026 | 751191395 |
| Principal investigator 1 | AbbVie Inc. | $7,103.95 | 04/30/2020 | Non-covered Recipient Entity CLINICAL RESEARCH OF WEST FLORIDA | M18-891 | No dispute reported | 06/30/2026 | 721163331 |
| Principal investigator 1 | Novo Nordisk AS | $1,000.00 | 04/23/2020 | Non-covered Recipient Entity CLINICAL RESEARCH OF WEST FLORIDA | NN9536-4374 | No dispute reported | 06/30/2026 | 742358445 |
| Principal investigator 1 | Novo Nordisk AS | $8,543.65 | 04/23/2020 | Non-covered Recipient Entity CLINICAL RESEARCH OF WEST FLORIDA | NN9536-4374 | No dispute reported | 06/30/2026 | 742358447 |
| Principal investigator 1 | AbbVie Inc. | $8,332.00 | 03/30/2020 | Non-covered Recipient Entity CLINICAL RESEARCH OF WEST FLORIDA | M18-891 | No dispute reported | 06/30/2026 | 721157935 |
| Principal investigator 1 | AbbVie Inc. | $1,691.90 | 03/30/2020 | Non-covered Recipient Entity CLINICAL RESEARCH OF WEST FLORIDA | M16-006 | No dispute reported | 06/30/2026 | 721158071 |
| Principal investigator 1 | Novo Nordisk AS | $3,235.40 | 03/26/2020 | Non-covered Recipient Entity CLINICAL RESEARCH OF WEST FLORIDA | NN9536-4374 | No dispute reported | 06/30/2026 | 742358443 |
| Principal investigator 1 | AbbVie Inc. | $8,230.65 | 03/12/2020 | Non-covered Recipient Entity CLINICAL RESEARCH OF WEST FLORIDA | M18-891 | No dispute reported | 06/30/2026 | 721155591 |
| Principal investigator 1 | AstraZeneca Pharmaceuticals LP | $3,583.04 | 03/03/2020 | Non-covered Recipient Entity Clinical Research Of West Florida | A Randomized Double-Blind Parallel Group Multi-Center 24-Week Study Comparing the Efficacy and Safety of Three Doses of PT001 to Placebo and Open-label Spiriva Respimat in Subjects With Persistent Asthma | No dispute reported | 06/30/2026 | 736748327 |
| Principal investigator 1 | Beckman Coulter, Inc. | $3,930.00 | 03/03/2020 | Non-covered Recipient Entity CLINICAL RESEARCH OF WEST FLORIDA INCORPORATED | HF Ref Interval (CHF-04-18) | No dispute reported | 06/30/2026 | 749968337 |
| Principal investigator 1 | JAZZ PHARMACEUTICALS INC. | $12,566.58 | 03/03/2020 | Non-covered Recipient Entity CLINICAL RESEARCH OF WEST FLORIDA INC | A DOUBLE-BLIND, PLACEBO-CONTROLLED, RANDOMIZED WITHDRAWAL, MULTICENTER STUDY OF THE EFFICACY AND SAFETY OF JZP-258 IN THE TREATMENT OF IDIOPATHIC HYPERSOMNIA (IH) WITH AN OPEN-LABEL SAFETY EXTENSION | No dispute reported | 06/30/2026 | 744483519 |
| Principal investigator 1 | AbbVie Inc. | $16,867.65 | 03/02/2020 | Non-covered Recipient Entity CLINICAL RESEARCH OF WEST FLORIDA | M18-891 | No dispute reported | 06/30/2026 | 721153911 |
| Principal investigator 1 | AbbVie Inc. | $2,425.75 | 02/28/2020 | Non-covered Recipient Entity CLINICAL RESEARCH OF WEST FLORIDA | M15-991 | No dispute reported | 06/30/2026 | 721152971 |
| Principal investigator 1 | Novo Nordisk AS | $4,913.37 | 02/25/2020 | Non-covered Recipient Entity CLINICAL RESEARCH OF WEST FLORIDA | NN9536-4374 | No dispute reported | 06/30/2026 | 742358441 |
| Principal investigator 1 | AbbVie Inc. | $2,000.00 | 02/24/2020 | Non-covered Recipient Entity CLINICAL RESEARCH OF WEST FLORIDA | M14-431 | No dispute reported | 06/30/2026 | 721151809 |
| Principal investigator 1 | AbbVie Inc. | $2,700.00 | 02/24/2020 | Non-covered Recipient Entity CLINICAL RESEARCH OF WEST FLORIDA | M14-430 | No dispute reported | 06/30/2026 | 721151811 |
| Principal investigator 1 | AbbVie Inc. | $3,400.00 | 02/24/2020 | Non-covered Recipient Entity CLINICAL RESEARCH OF WEST FLORIDA | M16-006 | No dispute reported | 06/30/2026 | 721151823 |
| Principal investigator 1 | AbbVie Inc. | $2,700.00 | 02/24/2020 | Non-covered Recipient Entity CLINICAL RESEARCH OF WEST FLORIDA | M16-000 | No dispute reported | 06/30/2026 | 721151825 |
| Principal investigator 1 | AbbVie Inc. | $3,400.00 | 02/20/2020 | Non-covered Recipient Entity CLINICAL RESEARCH OF WEST FLORIDA | M15-991 | No dispute reported | 06/30/2026 | 721151383 |
| Principal investigator 1 | JAZZ PHARMACEUTICALS INC. | $239.00 | 02/20/2020 | Non-covered Recipient Entity CLINICAL RESEARCH OF WEST FLORIDA INC | A DOUBLE-BLIND, PLACEBO-CONTROLLED, RANDOMIZED WITHDRAWAL, MULTICENTER STUDY OF THE EFFICACY AND SAFETY OF JZP-258 IN THE TREATMENT OF IDIOPATHIC HYPERSOMNIA (IH) WITH AN OPEN-LABEL SAFETY EXTENSION | No dispute reported | 06/30/2026 | 744483475 |
| Principal investigator 1 | JAZZ PHARMACEUTICALS INC. | $6.45 | 02/07/2020 | Non-covered Recipient Entity CLINICAL RESEARCH(W)FL | A DOUBLE-BLIND, PLACEBO-CONTROLLED, RANDOMIZED WITHDRAWAL, MULTICENTER STUDY OF THE EFFICACY AND SAFETY OF JZP-258 IN THE TREATMENT OF IDIOPATHIC HYPERSOMNIA (IH) WITH AN OPEN-LABEL SAFETY EXTENSION | No dispute reported | 06/30/2026 | 744483267 |
| Principal investigator 1 | JAZZ PHARMACEUTICALS INC. | $121.88 | 02/07/2020 | Non-covered Recipient Entity CLINICAL RESEARCH(W)FL | A DOUBLE-BLIND, PLACEBO-CONTROLLED, RANDOMIZED WITHDRAWAL, MULTICENTER STUDY OF THE EFFICACY AND SAFETY OF JZP-258 IN THE TREATMENT OF IDIOPATHIC HYPERSOMNIA (IH) WITH AN OPEN-LABEL SAFETY EXTENSION | No dispute reported | 06/30/2026 | 744483269 |
| Principal investigator 1 | JAZZ PHARMACEUTICALS INC. | $10.88 | 02/06/2020 | Non-covered Recipient Entity CLINICAL RESEARCH(W)FL | A DOUBLE-BLIND, PLACEBO-CONTROLLED, RANDOMIZED WITHDRAWAL, MULTICENTER STUDY OF THE EFFICACY AND SAFETY OF JZP-258 IN THE TREATMENT OF IDIOPATHIC HYPERSOMNIA (IH) WITH AN OPEN-LABEL SAFETY EXTENSION | No dispute reported | 06/30/2026 | 744483253 |
| Principal investigator 1 | AbbVie Inc. | $2,700.00 | 02/03/2020 | Non-covered Recipient Entity CLINICAL RESEARCH OF WEST FLORIDA | M14-433 | No dispute reported | 06/30/2026 | 721149165 |
| Principal investigator 1 | JAZZ PHARMACEUTICALS INC. | $21.76 | 02/03/2020 | Non-covered Recipient Entity CLINICAL RESEARCH(W)FL | A DOUBLE-BLIND, PLACEBO-CONTROLLED, RANDOMIZED WITHDRAWAL, MULTICENTER STUDY OF THE EFFICACY AND SAFETY OF JZP-258 IN THE TREATMENT OF IDIOPATHIC HYPERSOMNIA (IH) WITH AN OPEN-LABEL SAFETY EXTENSION | No dispute reported | 06/30/2026 | 744482889 |
| Principal investigator 1 | JAZZ PHARMACEUTICALS INC. | $21.76 | 02/01/2020 | Non-covered Recipient Entity CLINICAL RESEARCH(W)FL | A DOUBLE-BLIND, PLACEBO-CONTROLLED, RANDOMIZED WITHDRAWAL, MULTICENTER STUDY OF THE EFFICACY AND SAFETY OF JZP-258 IN THE TREATMENT OF IDIOPATHIC HYPERSOMNIA (IH) WITH AN OPEN-LABEL SAFETY EXTENSION | No dispute reported | 06/30/2026 | 744482531 |
| Principal investigator 1 | AbbVie Inc. | $11,272.55 | 01/30/2020 | Non-covered Recipient Entity CLINICAL RESEARCH OF WEST FLORIDA | M18-891 | No dispute reported | 06/30/2026 | 721147887 |
| Principal investigator 1 | Novo Nordisk AS | $2,899.96 | 01/28/2020 | Non-covered Recipient Entity CLINICAL RESEARCH OF WEST FLORIDA | NN9536-4374 | No dispute reported | 06/30/2026 | 742358439 |
| Principal investigator 1 | SANOFI US SERVICES INC. | $1,498.65 | 01/21/2020 | Non-covered Recipient Entity Clinical Research Of West Florida | A Randomized, Double-blind, Placebo-controlled, Parallel-group, Multicenter Study to Demonstrate the Effects of Sotagliflozin on Cardiovascular and Renal Events in Patients With Type 2 Diabetes, Cardiovascular Risk Factors and Moderately Impaired Renal Fu | No dispute reported | 06/30/2026 | 744084523 |
| Principal investigator 1 | Boehringer Ingelheim Pharmaceuticals, Inc. | $217,936.08 | 01/08/2020 | Non-covered Recipient Entity Clinical Research Of West Florida | Tio & Olo versus PBO stratified by PIFR | No dispute reported | 06/30/2026 | 751189345 |
| Principal investigator 1 | JAZZ PHARMACEUTICALS INC. | $21.76 | 01/04/2020 | Non-covered Recipient Entity CLINICAL RESEARCH(W)FL | A DOUBLE-BLIND, PLACEBO-CONTROLLED, RANDOMIZED WITHDRAWAL, MULTICENTER STUDY OF THE EFFICACY AND SAFETY OF JZP-258 IN THE TREATMENT OF IDIOPATHIC HYPERSOMNIA (IH) WITH AN OPEN-LABEL SAFETY EXTENSION | No dispute reported | 06/30/2026 | 744483055 |
| Principal investigator 1 | JAZZ PHARMACEUTICALS INC. | $21.76 | 01/04/2020 | Non-covered Recipient Entity CLINICAL RESEARCH(W)FL | A DOUBLE-BLIND, PLACEBO-CONTROLLED, RANDOMIZED WITHDRAWAL, MULTICENTER STUDY OF THE EFFICACY AND SAFETY OF JZP-258 IN THE TREATMENT OF IDIOPATHIC HYPERSOMNIA (IH) WITH AN OPEN-LABEL SAFETY EXTENSION | No dispute reported | 06/30/2026 | 744483057 |
| Principal investigator 1 | JAZZ PHARMACEUTICALS INC. | $6.50 | 01/04/2020 | Non-covered Recipient Entity CLINICAL RESEARCH(W)FL | A DOUBLE-BLIND, PLACEBO-CONTROLLED, RANDOMIZED WITHDRAWAL, MULTICENTER STUDY OF THE EFFICACY AND SAFETY OF JZP-258 IN THE TREATMENT OF IDIOPATHIC HYPERSOMNIA (IH) WITH AN OPEN-LABEL SAFETY EXTENSION | No dispute reported | 06/30/2026 | 744483059 |
| Principal investigator 1 | JAZZ PHARMACEUTICALS INC. | $10.88 | 01/04/2020 | Non-covered Recipient Entity CLINICAL RESEARCH(W)FL | A DOUBLE-BLIND, PLACEBO-CONTROLLED, RANDOMIZED WITHDRAWAL, MULTICENTER STUDY OF THE EFFICACY AND SAFETY OF JZP-258 IN THE TREATMENT OF IDIOPATHIC HYPERSOMNIA (IH) WITH AN OPEN-LABEL SAFETY EXTENSION | No dispute reported | 06/30/2026 | 744483061 |
| Principal investigator 1 | Boehringer Ingelheim Pharmaceuticals, Inc. | $6,651.49 | 01/01/2020 | Non-covered Recipient Entity Clinical Research Of West Florida Tampa | Tio & Olo versus PBO stratified by PIFR | No dispute reported | 06/30/2026 | 751191397 |
| Principal investigator 1 | Novartis Pharmaceuticals Corporation | $186,388.08 | 01/01/2020 | Non-covered Recipient Entity CLINICAL RESEARCH OF WEST FLORIDA | AN OPEN LABEL SINGLE ARM MULTI CENTER EXTENSION STUDY EVALUATING LONG TERM SAFETY TOLERABILITY AND EFFECTIVENESS OF OFATUMUMAB IN SUBJECTS WITH RELAPSING MULTIPLE SCLEROSIS | No dispute reported | 06/30/2026 | 721490551 |